<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NUCYNTA- tapentadol hydrochloride tablet, film coated </strong><br>Bryant Ranch Prepack<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
These highlights do not include all the information needed to use NUCYNTA safely and effectively. See full prescribing information for NUCYNTA . NUCYNTA (tapentadol) immediate-release oral tablets    C-II Initial U.S. Approval: 2008</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">NUCYNTA<span class="Sup">®</span> is an opioid analgesic indicated for the relief of moderate to severe <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> in patients 18 years of age or older. (<a href="#S1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>As with many centrally-acting analgesic medications, the dosing regimen of NUCYNTA<span class="Sup">®</span> should be individualized according to the severity of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> being treated, the previous experience with similar drugs and the ability to monitor the patient. (<a href="#S2">2</a>)</li>
<li> Initiate NUCYNTA<span class="Sup">®</span> with or without food at a dose of 50 mg, 75 mg, or 100 mg every 4 to 6 hours depending upon <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity. On the first day of dosing, the second dose may be administered as soon as one hour after the first dose, if adequate <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief is not attained with the first dose. Subsequent dosing is 50 mg, 75 mg, or 100 mg every 4 to 6 hours and should be adjusted to maintain adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> with acceptable tolerability. Daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not been studied and are, therefore, not recommended. (<a href="#S2">2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 50 mg, 75 mg, 100 mg (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Impaired pulmonary function (significant <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, acute or severe bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span> in unmonitored settings or the absence of resuscitative equipment) (<a href="#S4.1">4.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">Paralytic ileus</span> (<a href="#S4.2">4.2</a>)</li>
<li>Concomitant use with monoamine oxidase inhibitors (MAOI) or use within 14 days (<a href="#S4.3">4.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span>: Increased risk in elderly, debilitated patients, those suffering from conditions accompanied by <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, or upper airway obstruction. (<a href="#S5.1">5.1</a>)</li>
<li>CNS effects: Additive CNS depressive effects when used in conjunction with alcohol, other opioids, or illicit drugs. (<a href="#S5.2">5.2</a>)</li>
<li>Elevation of intracranial pressure: May be markedly exaggerated in the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, other intracranial lesions. (<a href="#S5.3">5.3</a>)</li>
<li>Abuse potential may occur. Monitor patients closely for signs of abuse and addiction. (<a href="#S5.4">5.4</a>)</li>
<li>Impaired mental/physical abilities: Caution must be used with potentially hazardous activities. (<a href="#S5.5">5.5</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>:  Use with caution in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. (<a href="#S5.7">5.7</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span>: Potentially life-threatening condition could result from concomitant serotonergic administration. (<a href="#S5.8">5.8</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse events were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>. (<a href="#S6">6</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. at 1-800-526-7736 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span></span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Use NUCYNTA<span class="Sup">®</span> with caution in patients currently using specified centrally-acting drugs or alcohol. (<a href="#S7.3">7.3</a>)</li>
<li>Do not use NUCYNTA<span class="Sup">®</span> in patients currently using or within 14 days of using a monoamine oxidase inhibitor (MAOI). (<a href="#S7.4">7.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Labor and delivery:  should not use during and immediately prior to labor and delivery. Monitor neonates, whose mothers have been taking NUCYNTA<span class="Sup">®</span>, for <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. (<a href="#S8.2">8.2</a>)</li>
<li>Nursing mothers: should not breast-feed. (<a href="#S8.3">8.3</a>)</li>
<li>Pediatric use: safety and effectiveness not established in patients less than 18 years of age. (<a href="#S8.4">8.4</a>)</li>
<li>Renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>: not recommended in patients with severe renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Use with caution in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<a href="#S8.6">8.6</a>,<a href="#S8.7"> 8.7</a>)</li>
<li>Elderly: care should be taken when selecting an initial dose. (<a href="#S2.3">2.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 3/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1    <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2    <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3    Elderly Patients</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1   Impaired Pulmonary Function</a></h2>
<h2><a href="#section-4.2" class="toc">4.2    <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">Paralytic Ileus</span></a></h2>
<h2><a href="#section-4.3" class="toc">4.3   Monoamine Oxidase Inhibitors</a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1    <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2    <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS Depression</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3   <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4   Misuse and Abuse</a></h2>
<h2><a href="#section-5.5" class="toc">5.5   Driving and Operating Machinery</a></h2>
<h2><a href="#section-5.6" class="toc">5.6    Interactions with Alcohol and Drugs of Abuse</a></h2>
<h2><a href="#section-5.7" class="toc">5.7    <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8    <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> Risk</a></h2>
<h2><a href="#section-5.9" class="toc">5.9   Withdrawal</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11  Use in Pancreatic/<span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">Biliary Tract Disease</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1    Commonly-Observed Treatment-Emergent Adverse Events in Double-Blind Controlled Clinical Trials</a></h2>
<h2><a href="#section-6.2" class="toc">6.2    Other Adverse Reactions Observed During the Premarketing Evaluation of NUCYNTA<span class="Sup">®</span></a></h2>
<h2><a href="#section-6.3" class="toc">6.3   Post-marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1    Drugs Metabolized by Cytochrome P450 Enzymes</a></h2>
<h2><a href="#section-7.2" class="toc">7.2   Drugs That Inhibit or Induce Cytochrome P450 Enzymes</a></h2>
<h2><a href="#section-7.3" class="toc">7.3    Centrally-Acting Drugs and Alcohol</a></h2>
<h2><a href="#section-7.4" class="toc">7.4    Monoamine Oxidase Inhibitors</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6    <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7    <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2 Abuse</a></h2>
<h2><a href="#section-9.3" class="toc">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-10.1" class="toc">10.1 Human Experience</a></h2>
<h2><a href="#section-10.2" class="toc">10.2  Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></a></h2>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NON-CLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-13.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1  Orthopedic Surgery – Bunionectomy</a></h2>
<h2><a href="#section-14.2" class="toc">14.2  End-Stage <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Degenerative Joint Disease</span></a></h2>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Instructions for Use</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 Misuse and Abuse</a></h2>
<h2><a href="#section-15.3" class="toc">17.3 Interference with Cognitive and Motor Performance</a></h2>
<h2><a href="#section-15.4" class="toc">17.4 Pregnancy</a></h2>
<h2><a href="#section-15.5" class="toc">17.5 Nursing</a></h2>
<h2><a href="#section-15.6" class="toc">17.6  Monoamine Oxidase Inhibitors</a></h2>
<h2><a href="#section-15.7" class="toc">17.7  <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></a></h2>
<h2><a href="#section-15.8" class="toc">17.8  <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></a></h2>
<h2><a href="#section-15.9" class="toc">17.9  Alcohol</a></h2>
<h2><a href="#section-15.10" class="toc">17.10 Medication Guide</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">As with many centrally-acting analgesic medications, the dosing regimen should be individualized according to the severity of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> being treated, the previous experience with similar drugs and the ability to monitor the patient.</p>
<p>The dose is 50 mg, 75 mg, or 100 mg every 4 to 6 hours depending upon <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity.</p>
<p>On the first day of dosing, the second dose may be administered as soon as one hour after the first dose, if adequate <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief is not attained with the first dose. Subsequent dosing is 50 mg, 75 mg, or 100 mg every 4 to 6 hours and should be adjusted to maintain adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> with acceptable tolerability.</p>
<p>Daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not been studied and are not recommended.</p>
<p>NUCYNTA<span class="Sup">®</span> may be given with or without food <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>].</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1    <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No dosage adjustment is recommended in patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>NUCYNTA<span class="Sup">®</span> has not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. The use in this population is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2    <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No dosage adjustment is recommended in patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>NUCYNTA<span class="Sup">®</span> should be used with caution in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Treatment in these patients should be initiated at 50 mg with the interval between doses no less than every 8 hours (maximum of three doses in 24 hours). Further treatment should reflect maintenance of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> with acceptable tolerability, to be achieved by either shortening or lengthening the dosing interval <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>NUCYNTA<span class="Sup">®</span> has not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and use in this population is not recommended <span class="Italics">[see<a href="#S5.10"> Warnings and Precautions (5.10)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3    Elderly Patients</h2>
<p class="First">In general, recommended dosing for elderly patients with normal renal and hepatic function is the same as for younger adult patients with normal renal and hepatic function. Because elderly patients are more likely to have decreased renal and hepatic function, consideration should be given to starting elderly patients with the lower range of recommended doses.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">NUCYNTA<span class="Sup">®</span> Tablets are round, biconvex and film-coated and are available in the following strengths, colors, and debossings: 50 mg of tapentadol (yellow with "O-M" on one side and "50" on the other side), 75 mg of tapentadol (yellow-orange with "O-M" on one side and "75" on the other side), and 100 mg of tapentadol (orange with "O-M" on one side and "100" on the other side).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1   Impaired Pulmonary Function</h2>
<p class="First">Like other drugs with mu-opioid agonist activity, NUCYNTA<span class="Sup">®</span> is contraindicated in patients with significant <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in unmonitored settings or the absence of resuscitative equipment. NUCYNTA<span class="Sup">®</span> is also contraindicated in patients with acute or severe bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span> in unmonitored settings or the absence of resuscitative equipment <span class="Italics">[see<a href="#S5.1"> Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.2"></a><a name="section-4.2"></a><p></p>
<h2>4.2    <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">Paralytic Ileus</span></h2>
<p class="First">Like drugs with mu-opioid agonist activity, NUCYNTA<span class="Sup">®</span> is contraindicated in any patient who has or is suspected of having <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.3"></a><a name="section-4.3"></a><p></p>
<h2>4.3   Monoamine Oxidase Inhibitors</h2>
<p class="First">NUCYNTA<span class="Sup">®</span> is contraindicated in patients who are receiving monoamine oxidase (MAO) inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels which may result in adverse cardiovascular events <span class="Italics">[see<a href="#S7.4"> Drug Interactions (7.4)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1    <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> is the primary risk of mu-opioid agonists. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> occurs more frequently in elderly or debilitated patients and in those suffering from conditions accompanied by <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, or upper airway obstruction, in whom even moderate therapeutic doses may significantly decrease pulmonary ventilation.</p>
<p>NUCYNTA<span class="Sup">®</span> should be administered with caution to patients with conditions accompanied by <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span> or decreased respiratory reserve such as: <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> or <span class="product-label-link" type="condition" conceptid="4307356" conceptname="Cor pulmonale">cor pulmonale</span>, severe <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea syndrome</span>, <span class="product-label-link" type="condition" conceptid="4182596" conceptname="Myxedema">myxedema</span>, kyphoscoliosis, central nervous system (CNS) <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. In such patients, even usual therapeutic doses of NUCYNTA<span class="Sup">®</span> may increase airway resistance and decrease respiratory drive to the point of <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>. Alternative non-mu-opioid agonist analgesics should be considered and NUCYNTA<span class="Sup">®</span> should be employed only under careful medical supervision at the lowest effective dose in such patients. If <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> occurs, it should be treated as any mu-opioid agonist-induced <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> <span class="Italics">[see<a href="#S10.2"> Overdosage (10.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2    <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS Depression</span></h2>
<p class="First">Patients receiving other mu-opioid agonist analgesics, general anesthetics, phenothiazines, other tranquilizers, sedatives, hypnotics, or other CNS depressants (including alcohol) concomitantly with NUCYNTA<span class="Sup">®</span> may exhibit additive <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. Interactive effects resulting in <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, profound sedation, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may result if these drugs are taken in combination with NUCYNTA<span class="Sup">®</span>. When such combined therapy is contemplated, a dose reduction of one or both agents should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3   <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span></h2>
<p class="First">Opioid analgesics can raise cerebrospinal fluid pressure as a result of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> with <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> retention. Therefore, NUCYNTA<span class="Sup">®</span> should not be used in patients who may be susceptible to the effects of raised cerebrospinal fluid pressure such as those with evidence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>. Opioid analgesics may obscure the clinical course of patients with <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span> due to effects on pupillary response and consciousness. NUCYNTA<span class="Sup">®</span> should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, intracranial lesions, or other sources of preexisting <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4   Misuse and Abuse</h2>
<p class="First">Tapentadol is a mu-opioid agonist and is a Schedule II controlled substance. Such drugs are sought by drug abusers and people with addiction disorders. Diversion of Schedule II products is an act subject to criminal penalty.</p>
<p>NUCYNTA<span class="Sup">®</span> can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing NUCYNTA<span class="Sup">®</span> in situations where the physician or pharmacist is concerned about an increased risk of misuse and abuse. Concerns about abuse and addiction should not prevent the proper management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. However, all patients treated with mu-opioid agonists require careful monitoring for signs of abuse and addiction, since use of mu-opioid agonist analgesic products carry the risk of addiction even under appropriate medical use <span class="Italics">[see<a href="#S9.2"> Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (9.2)</a>]</span>.</p>
<p>NUCYNTA<span class="Sup">®</span> may be abused by crushing, chewing, snorting or injecting the product. These practices pose a significant risk to the abuser that could result in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> <span class="Italics">[see<a href="#S9"> Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (9)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5   Driving and Operating Machinery</h2>
<p class="First">Patients should be cautioned that NUCYNTA<span class="Sup">®</span> may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. This is to be expected especially at the beginning of treatment, at any change of dosage as well as in combination with alcohol or tranquilizers<span class="Italics"> [see<a href="#S7.3"> Drug Interactions (7.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6    Interactions with Alcohol and Drugs of Abuse</h2>
<p class="First">Due to its mu-opioid agonist activity, NUCYNTA<span class="Sup">®</span> may be expected to have additive effects when used in conjunction with alcohol, opioids, or illicit drugs that cause central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and profound sedation, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> <span class="Italics">[see<a href="#S7.3"> Drug Interactions (7.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7    <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></h2>
<p class="First">NUCYNTA<span class="Sup">®</span> has not been systematically evaluated in patients with a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder, and such patients were excluded from clinical studies. NUCYNTA<span class="Sup">®</span> should be prescribed with care in patients with a history of a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder or any condition that would put the patient at risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8    <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> Risk</h2>
<p class="First">The development of a potentially life-threatening <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> may occur with use of Serotonin and Norepinephrine Reuptake Inhibitor (SNRI) products, including NUCYNTA<span class="Sup">®</span>, particularly with concomitant use of serotonergic drugs such as Selective Serotonin Reuptake Inhibitors (SSRIs), SNRIs, tricyclic antidepressants (TCAs), MAOIs and triptans, and with drugs that impair metabolism of serotonin (including MAOIs). This may occur within the recommended dose. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> may include mental-status changes (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular aberrations (e.g., <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>) and/or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9   Withdrawal</h2>
<p class="First">Withdrawal symptoms may occur if NUCYNTA<span class="Sup">®</span> is discontinued abruptly. These symptoms may include: <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, upper respiratory symptoms, <span class="product-label-link" type="condition" conceptid="4224957" conceptname="Piloerection">piloerection</span>, and rarely, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>. Withdrawal symptoms may be reduced by tapering NUCYNTA<span class="Sup">®</span><span class="Italics"> [see<a href="#S9.3"> Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (9.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">A study of NUCYNTA<span class="Sup">®</span> in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> showed higher serum concentrations than in those with normal hepatic function. NUCYNTA<span class="Sup">®</span> should be used with caution in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see<a href="#S2.2"> Dosage and Administration (2.2) </a>and<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>NUCYNTA<span class="Sup">®</span> has not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and, therefore, use in this population is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11  Use in Pancreatic/<span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">Biliary Tract Disease</span></h2>
<p class="First">Like other drugs with mu-opioid agonist activity, NUCYNTA<span class="Sup">®</span> may cause spasm of the sphincter of Oddi and should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">biliary tract disease</span>, including <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following treatment-emergent adverse events are discussed in more detail in other sections of the labeling:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span> <span class="Italics">[see<a href="#S4.1"> Contraindications (4.1) </a>and<a href="#S5.1"> Warnings and Precautions (5.1)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS Depression</span><span class="Italics"> [see<a href="#S5.2"> Warnings and Precautions (5.2)</a>]</span>
</li>
</ul>
<p>Because clinical studies are conducted under widely varying conditions, adverse event rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice. A treatment-emergent adverse event refers to any untoward medical event associated with the use of the drug in humans, whether or not considered drug-related.</p>
<p>Based on data from nine Phase 2/3 studies that administered multiple doses (seven placebo- and/or active-controlled, one noncontrolled and one Phase 3 active-controlled safety study) the most common adverse events (reported by ≥10% in any NUCYNTA<span class="Sup">®</span> dose group) were: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.</p>
<p>The most common reasons for discontinuation due to adverse events in the studies described above (reported by ≥1% in any NUCYNTA<span class="Sup">®</span> dose group) were <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (2.6% vs. 0.5%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (2.3% vs. 0.6%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (1.4% vs. 0.2%), <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (1.3% vs. 0.2%) and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (0.9% vs. 0.2%) for NUCYNTA<span class="Sup">®</span>- and placebo-treated patients, respectively.</p>
<p>Seventy-six percent of NUCYNTA<span class="Sup">®</span>-treated patients from the nine studies experienced adverse events.</p>
<p>NUCYNTA<span class="Sup">®</span> was studied in multiple-dose, active- or placebo-controlled studies, or noncontrolled studies (n = 2178), in single-dose studies (n = 870), in open-label study extension (n = 483) and in Phase 1 studies (n = 597). Of these, 2034 patients were treated with doses of 50 mg to 100 mg of NUCYNTA<span class="Sup">®</span> dosed every 4 to 6 hours.</p>
<p>The data described below reflect exposure to NUCYNTA<span class="Sup">®</span> in 3161 patients, including 449 exposed for 45 days. NUCYNTA<span class="Sup">®</span> was studied primarily in placebo- and active-controlled studies (n = 2266, and n = 2944, respectively). The population was 18 to 85 years old (mean age 46 years), 68% were female, 75% white and 67% were postoperative. Most patients received NUCYNTA<span class="Sup">®</span> doses of 50 mg, 75 mg, or 100 mg every 4 to 6 hours.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1    Commonly-Observed Treatment-Emergent Adverse Events in Double-Blind Controlled Clinical Trials</h2>
<p class="First">Table 1 lists the adverse events reported in ≥1% or more of NUCYNTA<span class="Sup">®</span>-treated patients with acute moderate to severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the pooled safety data from nine Phase 2/3 studies that administered multiple doses (seven placebo- and/or active-controlled, one noncontrolled, and one Phase 3 active-controlled safety study).</p>
<table width="100%">
<caption><span>Table 1	Treatment-Emergent Adverse Events<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> Reported by ≥1% of NUCYNTA<span class="Sup">®</span>-Treated Patients In Seven Phase 2/3 Placebo- and/or Oxycodone-Controlled, One Noncontrolled, and One Phase 3 Oxycodone-Controlled Safety, Multiple-Dose Clinical Studies</span></caption>
<col align="left" valign="top" width="2%">
<col align="left" valign="top" width="38%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left" colspan="2">System/Organ Class</th>
<th class="Rrule" align="center">NUCYNTA<span class="Sup">®</span>
</th>
<th class="Rrule" align="center">Placebo</th>
</tr>
<tr>
<th class="Lrule" align="left"></th>
<th class="Rrule" align="left"> MedDRA Preferred Term</th>
<th class="Rrule" align="center">21 mg – 120 mg</th>
<th class="Rrule" align="center">(n=619)</th>
</tr>
<tr>
<th class="Lrule" align="left"></th>
<th class="Rrule" align="left"></th>
<th class="Rrule" align="center">(n=2178)</th>
<th class="Rrule" align="center">%</th>
</tr>
<tr class="Last">
<th class="Lrule" align="left"></th>
<th class="Rrule" align="left"></th>
<th class="Rrule" align="center">%</th>
<th class="Rrule" align="center"></th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>A treatment-emergent adverse event refers to any untoward medical event associated with the use of the drug in humans, whether or not considered drug-related.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left" colspan="2"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule Toprule" align="center">30</td>
<td class="Rrule Toprule" align="center">13</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule Toprule" align="center">18</td>
<td class="Rrule Toprule" align="center">4</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule Toprule" align="center">8</td>
<td class="Rrule Toprule" align="center">3</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Rrule Toprule" align="center">4</td>
<td class="Rrule Toprule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Rrule Toprule" align="center">2</td>
<td class="Rrule Toprule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" colspan="2">General disorders and administration site conditions</td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule Toprule" align="center">3</td>
<td class="Rrule Toprule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4141161" conceptname="Hot">Feeling hot</span></td>
<td class="Rrule Toprule" align="center">1</td>
<td class="Rrule Toprule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" colspan="2"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td class="Rrule Toprule" align="center">1</td>
<td class="Rrule Toprule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td class="Rrule Toprule" align="center">1</td>
<td class="Rrule Toprule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td class="Rrule Toprule" align="center">1</td>
<td class="Rrule Toprule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" colspan="2">Metabolism and nutrition disorders</td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></td>
<td class="Rrule Toprule" align="center">2</td>
<td class="Rrule Toprule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" colspan="2">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Rrule Toprule" align="center">1</td>
<td class="Rrule Toprule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" colspan="2"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule Toprule" align="center">24</td>
<td class="Rrule Toprule" align="center">8</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Rrule Toprule" align="center">15</td>
<td class="Rrule Toprule" align="center">3</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td class="Rrule Toprule" align="center">1</td>
<td class="Rrule Toprule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></td>
<td class="Rrule Toprule" align="center">1</td>
<td class="Rrule Toprule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" colspan="2">Psychiatric disorders</td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Rrule Toprule" align="center">2</td>
<td class="Rrule Toprule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusional state</span></td>
<td class="Rrule Toprule" align="center">1</td>
<td class="Rrule Toprule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Abnormal dreams</span></td>
<td class="Rrule Toprule" align="center">1</td>
<td class="Rrule Toprule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td class="Rrule Toprule" align="center">1</td>
<td class="Rrule Toprule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" colspan="2">Skin and subcutaneous tissue disorders</td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Rrule Toprule" align="center">5</td>
<td class="Rrule Toprule" align="center">1</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span></td>
<td class="Rrule Toprule" align="center">3</td>
<td class="Rrule Toprule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4172849" conceptname="Generalized pruritus">Pruritus generalized</span></td>
<td class="Rrule Toprule" align="center">3</td>
<td class="Rrule Toprule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule Toprule" align="center">1</td>
<td class="Rrule Toprule" align="center">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" colspan="2"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Toprule" align="left"></td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot flush</span></td>
<td class="Rrule Toprule" align="center">1</td>
<td class="Rrule Toprule" align="center">&lt;1</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2    Other Adverse Reactions Observed During the Premarketing Evaluation of NUCYNTA<span class="Sup">®</span>
</h2>
<p class="First">The following adverse drug reactions occurred in &lt;1% of NUCYNTA<span class="Sup">®</span>-treated patients in the pooled safety data from nine Phase 2/3 studies that administered multiple doses (seven were placebo- and/or active-controlled, one noncontrolled, and one Phase 3 active-controlled safety study):</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>: </span><span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">heart rate increased</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">heart rate decreased</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="4010028" conceptname="Impaired gastric emptying">impaired gastric emptying</span></p>
<p><span class="Bold">General disorders and administration site conditions: </span><span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="441260" conceptname="Drug withdrawal">drug withdrawal syndrome</span>, <span class="product-label-link" type="condition" conceptid="4012565" conceptname="Feeling intoxicated">feeling drunk</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span></p>
<p><span class="Bold">Investigations: </span>gamma-glutamyltransferase increased, <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> increased, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> increased</p>
<p><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span>: </span>involuntary muscle contractions, <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">sensation of heaviness</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">disturbance in attention</span>, sedation, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">depressed level of consciousness</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4142895" conceptname="Near syncope">presyncope</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>,  <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">coordination abnormal</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span></p>
<p><span class="Bold">Psychiatric disorders:</span> <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoric mood</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">thinking abnormal</span></p>
<p><span class="Bold">Renal and urinary disorders:</span> <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">urinary hesitation</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">pollakiuria</span></p>
<p><span class="Bold">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>: </span>oxygen saturation decreased, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span></p>
<p><span class="Bold">Skin and subcutaneous tissue disorders: </span><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">blood pressure decreased</span></p>
<p>In the pooled safety data, the overall incidence of adverse reactions increased with increased dose of NUCYNTA<span class="Sup">®</span>, as did the percentage of patients with adverse reactions of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.3"></a><a name="section-6.3"></a><p></p>
<h2>6.3   Post-marketing Experience</h2>
<p class="First">The following additional adverse reactions have been identified during post-approval use of NUCYNTA<span class="Sup">®</span>. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span>: </span><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>: </span><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></p>
<p><span class="Bold">Psychiatric disorders: </span><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">NUCYNTA<span class="Sup">®</span> is mainly metabolized by glucuronidation. The following substances have been included in a set of interaction studies without any clinically significant finding: acetaminophen, acetylsalicylic acid, naproxen and probenecid <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>The pharmacokinetics of tapentadol were not affected when gastric pH or gastrointestinal motility were increased by omeprazole and metoclopramide, respectively <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1    Drugs Metabolized by Cytochrome P450 Enzymes</h2>
<p class="First"><span class="Italics">In vitro</span> investigations indicate that NUCYNTA<span class="Sup">®</span> does not inhibit or induce P450 enzymes. Thus, clinically relevant interactions mediated by the cytochrome P450 system are unlikely to occur <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2   Drugs That Inhibit or Induce Cytochrome P450 Enzymes</h2>
<p class="First">The major pathway of tapentadol metabolism is conjugation with glucuronic acid to produce glucuronides. To a lesser extent, tapentadol is additionally metabolized to N-desmethyl tapentadol (13%) by CYP2C9 and CYP2C19 to hydroxy tapentadol (2%) by CYP2D6, which are further metabolized by conjugation. Since only a minor amount of NUCYNTA<span class="Sup">®</span> is metabolized via the oxidative pathway clinically relevant interactions mediated by the cytochrome P450 system are unlikely to occur <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3    Centrally-Acting Drugs and Alcohol</h2>
<p class="First">Patients receiving other opioid agonist analgesics, general anesthetics, phenothiazines, antiemetics, other tranquilizers, sedatives, hypnotics, or other CNS depressants (including alcohol) concomitantly with NUCYNTA<span class="Sup">®</span> may exhibit an additive <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. Interactive effects resulting in <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, profound sedation, or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> may result if these drugs are taken in combination with NUCYNTA<span class="Sup">®</span>. When such combined therapy is contemplated, a dose reduction of one or both agents should be considered <span class="Italics">[see<a href="#S5.2"> Warnings and Precautions (5.2) </a>and<a href="#S5.6"> (5.6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4    Monoamine Oxidase Inhibitors</h2>
<p class="First">NUCYNTA<span class="Sup">®</span> is contraindicated in patients who are receiving monoamine oxidase (MAO) inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels which may result in adverse cardiovascular events <span class="Italics">[see<a href="#S4.3"> Contraindications (4.3)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C.</p>
<p>Tapentadol HCl was evaluated for teratogenic effects in pregnant rats and rabbits following intravenous and subcutaneous exposure during the period of embryofetal organogenesis. When tapentadol was administered twice daily by the subcutaneous route in rats at dose levels of 10, 20, or 40 mg/kg/day [producing up to 1 times the plasma exposure at the maximum recommended human dose (MRHD) of 700 mg/day based on an area under the time-curve (AUC) comparison], no teratogenic effects were observed. Evidence of embryofetal toxicity included transient delays in skeletal maturation (i.e. reduced ossification) at the 40 mg/kg/day dose which was associated with significant maternal toxicity. Administration of tapentadol HCl in rabbits at doses of 4, 10, or 24 mg/kg/day by subcutaneous injection [producing 0.2, 0.6, and 1.85 times the plasma exposure at the MRHD based on an AUC comparison] revealed embryofetal toxicity at doses ≥ 10 mg/kg/day. Findings included reduced fetal viability, skeletal delays and other variations. In addition, there were multiple malformations including <span class="product-label-link" type="condition" conceptid="4218764" conceptname="Gastroschisis">gastroschisis</span>/thoracogastroschisis, amelia/<span class="product-label-link" type="condition" conceptid="73307" conceptname="Transverse deficiency of lower limb">phocomelia</span>, and <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> at doses ≥ 10 mg/kg/day and above, and ablepharia, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, and <span class="product-label-link" type="condition" conceptid="4283381" conceptname="Spina bifida">spina bifida</span> at the high dose of 24 mg/kg/day. Embryofetal toxicity, including malformations, may be secondary to the significant maternal toxicity observed in the study.</p>
<p>In a study of pre- and postnatal development in rats, oral administration of tapentadol at doses of 20, 50, 150, or 300 mg/kg/day to pregnant and lactating rats during the late gestation and early postnatal period [resulting in up to 1.7 times the plasma exposure at the MRHD on an AUC basis] did not influence physical or reflex development, the outcome of neurobehavioral tests or reproductive parameters. Treatment-related <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delay</span> was observed, including incomplete ossification, and significant reductions in pup body weights and body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gains</span> at doses associated with maternal toxicity (150 mg/kg/day and above). At maternal tapentadol doses ≥ 150 mg/kg/day, a dose-related increase in pup mortality was observed through postnatal Day 4.</p>
<p>There are no adequate and well controlled studies of NUCYNTA<span class="Sup">®</span> in pregnant women. NUCYNTA<span class="Sup">®</span> should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="S8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">The effect of tapentadol on labor and delivery in humans is unknown. NUCYNTA<span class="Sup">®</span> is not recommended for use in women during and immediately prior to labor and delivery. Due to the mu-opioid receptor agonist activity of NUCYNTA<span class="Sup">®</span>, neonates whose mothers have been taking NUCYNTA<span class="Sup">®</span> should be monitored for <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. A specific opioid antagonist, such as naloxone, should be available for reversal of opioid induced <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the neonate.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">There is insufficient/limited information on the excretion of tapentadol in human or animal breast milk. Physicochemical and available pharmacodynamic/toxicological data on tapentadol point to excretion in breast milk and risk to the suckling child cannot be excluded. NUCYNTA<span class="Sup">®</span> should not be used during breast-feeding.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of NUCYNTA<span class="Sup">®</span> in pediatric patients less than 18 years of age have not been established. NUCYNTA<span class="Sup">®</span> is not recommended in this population.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of patients in Phase 2/3 double-blind, multiple-dose clinical studies of NUCYNTA<span class="Sup">®</span>, 19% were 65 and over, while 5% were 75 and over. No overall differences in effectiveness were observed between these patients and younger patients. The rate of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> was higher in subjects greater than or equal to 65 years than those less than 65 years (12% vs. 7%).</p>
<p>In general, recommended dosing for elderly patients with normal renal and hepatic function is the same as for younger adult patients with normal renal and hepatic function. Because elderly patients are more likely to have decreased renal and hepatic function, consideration should be given to starting elderly patients with the lower range of recommended doses <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.6"></a><p></p>
<h2>8.6    <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">In patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the safety and effectiveness of NUCYNTA<span class="Sup">®</span> has not been established. NUCYNTA<span class="Sup">®</span> is not recommended in this population <span class="Italics">[see<a href="#S2.1"> Dosage and Administration (2.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.7"></a><p></p>
<h2>8.7    <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Administration of NUCYNTA<span class="Sup">®</span> resulted in higher exposures and serum levels to tapentadol in subjects with impaired hepatic function compared to subjects with normal hepatic function <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>. NUCYNTA<span class="Sup">®</span> should be used with caution in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see<a href="#S2.2"> Dosage and Administration (2.2)</a>]</span>.</p>
<p>NUCYNTA<span class="Sup">®</span> has not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, therefore, use of NUCYNTA<span class="Sup">®</span> is not recommended in this population <span class="Italics">[see<a href="#S5.10"> Warnings and Precautions (5.10)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="S9"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="S9.1"></a><a name="section-9.1"></a><p></p>
<h2>9.1 Controlled Substance</h2>
<p class="First">NUCYNTA<span class="Sup">®</span> contains tapentadol, a mu-opioid agonist and is a Schedule II controlled substance. NUCYNTA<span class="Sup">®</span> has an abuse potential similar to hydromorphone, can be abused and is subject to criminal diversion.</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="S9.2"></a><a name="section-9.2"></a><p></p>
<h2>9.2 Abuse</h2>
<p class="First">Addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span> is a treatable disease, utilizing a multidisciplinary approach, but relapse is common.</p>
<p>Concerns about abuse and addiction should not prevent the proper management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. However, all patients treated with opioids require careful monitoring for signs of abuse and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use.</p>
<p>"Drug seeking" behavior is very common in addicts, and drug abusers. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated claims of loss of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating physician(s). "Doctor shopping" (visiting multiple prescribers) to obtain additional prescriptions is common among drug abusers and people suffering from untreated addiction. Preoccupation with achieving adequate <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief can be appropriate behavior in a patient with poor <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> control.</p>
<p>Abuse and addiction are separate and distinct from physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance. Physicians should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> in all addicts. In addition, abuse of mu-opioid agonists can occur in the absence of true addiction and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances. Careful recordkeeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised.</p>
<p>Abuse of NUCYNTA<span class="Sup">®</span> poses a risk of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. This risk is increased with concurrent abuse of NUCYNTA<span class="Sup">®</span> with alcohol and other substances. In addition, parenteral drug abuse is commonly associated with transmission of infectious diseases such as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and HIV.</p>
<p>Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of drugs with mu-opioid agonist properties.</p>
<p>Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal symptoms <span class="Italics">[see<a href="#S5.1"> Warnings and Precautions (5.1)</a>]</span>. Use of NUCYNTA<span class="Sup">®</span> in this population has not been characterized. As NUCYNTA<span class="Sup">®</span> has mu-opioid agonist activity, infants whose mothers have taken NUCYNTA<span class="Sup">®</span>, should be carefully monitored.</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="S9.3"></a><a name="section-9.3"></a><p></p>
<h2>9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">Tolerance is the need for increasing doses of opioids to maintain a defined effect such as <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> (in the absence of disease progression or other external factors). Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is manifested by withdrawal symptoms after abrupt discontinuation of a drug or upon administration of an antagonist<span class="Bold">.</span></p>
<p>The opioid abstinence or withdrawal syndrome is characterized by some or all of the following: <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, perspiration, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>. Other symptoms also may develop, including <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, or heart rate.</p>
<p>Generally, tolerance and/or withdrawal are more likely to occur the longer a patient is on continuous opioid therapy. In a safety study where drug was administered up to 90 days, 82.7% of patients taking NUCYNTA<span class="Sup">®</span> who stopped abruptly without initiating alternative therapy and were assessed 2 to 4 days after discontinuation, did not have objective signs of opioid withdrawal using the Clinical Opiate Withdrawal Scale. Moderate withdrawal symptoms were seen in 0.3% of patients with the rest (17%) experiencing mild symptoms. Withdrawal symptoms may be reduced by tapering NUCYNTA<span class="Sup">®</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S10.1"></a><a name="section-10.1"></a><p></p>
<h2>10.1 Human Experience</h2>
<p class="First">Experience with NUCYNTA<span class="Sup">®</span> <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is very limited. Preclinical data suggest that symptoms similar to those of other centrally acting analgesics with mu-opioid agonist activity are to be expected upon <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> with tapentadol. In principle, these symptoms may particularly appear in the clinical setting: <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, consciousness disorders up to <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> up to <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S10.2"></a><a name="section-10.2"></a><p></p>
<h2>10.2  Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></h2>
<p class="First">Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should be focused on treating symptoms of mu-opioid agonism. Primary attention should be given to re-establishment of a patent airway and institution of assisted or controlled ventilation when <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of NUCYNTA<span class="Sup">®</span> is suspected. Supportive measures (including oxygen and vasopressors) should be employed in the management of circulatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> accompanying <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> as indicated. <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span> or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> may require cardiac massage or defibrillation.</p>
<p>Pure opioid antagonists, such as naloxone, are specific antidotes to <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> resulting from opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> following an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may outlast the duration of action of the opioid antagonist. Administration of an opioid antagonist is not a substitute for continuous monitoring of airway, breathing, and circulation following an opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. If the response to opioid antagonists is suboptimal or only brief in nature, an additional antagonist should be administered as directed by the manufacturer of the product.</p>
<p>Gastrointestinal decontamination may be considered in order to eliminate unabsorbed drug. Gastrointestinal decontamination with activated charcoal or by gastric lavage is only recommended within 2 hours after intake. Gastrointestinal decontamination at a later time point may be useful in case of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> with exceptionally large quantities. Before attempting gastrointestinal decontamination, care should be taken to secure the airway.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">NUCYNTA<span class="Sup">®</span> (tapentadol) Tablets are immediate-release film-coated tablets for oral administration. The chemical name is 3-[(1<span class="Italics">R</span>,2<span class="Italics">R</span>)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol monohydrochloride. The structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da748c7a-d2ae-1cbc-6f1a-8a6fc0402560&amp;name=nucynta-01.jpg"></div>
<p>The molecular weight of tapentadol HCl is 257.80, and the molecular formula is C<span class="Sub">14</span>H<span class="Sub">23</span>NO•HCl. The n-octanol:water partition coefficient log P value is 2.87. The pKa values are 9.34 and 10.45. In addition to the active ingredient tapentadol HCl, tablets also contain the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, povidone, magnesium stearate, and Opadry<span class="Sup">®</span> II, a proprietary film-coating mixture containing polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and aluminum lake coloring.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Tapentadol is a centrally-acting synthetic analgesic. Although its exact mechanism is unknown, analgesic efficacy is thought to be due to mu-opioid agonist activity and the inhibition of norepinephrine reuptake.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Tapentadol is a centrally-acting synthetic analgesic. It is 18 times less potent than morphine in binding to the human mu-opioid receptor and is 2–3 times less potent in producing <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> in animal models. Tapentadol has been shown to inhibit norepinephrine reuptake in the brains of rats resulting in increased norepinephrine concentrations. In preclinical models, the analgesic activity due to the mu-opioid receptor agonist activity of tapentadol can be antagonized by selective mu-opioid antagonists (e.g., naloxone), whereas the norepinephrine reuptake inhibition is sensitive to norepinephrine modulators. Tapentadol exerts its <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effects</span> without a pharmacologically active metabolite.</p>
<p>Effects on the cardiovascular system: There was no effect of therapeutic and supratherapeutic doses of tapentadol on the QT interval. In a randomized, double-blind, placebo- and positive-controlled crossover study, healthy subjects were administered five consecutive doses of NUCYNTA<span class="Sup">®</span> 100 mg every 6 hours, NUCYNTA<span class="Sup">®</span> 150 mg every 6 hours, placebo and a single oral dose of moxifloxacin. Similarly, NUCYNTA<span class="Sup">®</span> had no relevant effect on other ECG parameters (heart rate, PR interval, QRS duration, T-wave or U-wave morphology).</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.1"></a><p></p>
<p class="First"><span class="Italics Underline">Absorption</span></p>
<p>Mean absolute bioavailability after single-dose administration (fasting) is approximately 32% due to extensive first-pass metabolism. Maximum serum concentrations of tapentadol are typically observed at around 1.25 hours after dosing.</p>
<p>Dose-proportional increases in the C<span class="Sub">max</span> and AUC values of tapentadol have been observed over the 50 to 150 mg dose range.</p>
<p>A multiple (every 6 hour) dose study with doses ranging from 75 to 175 mg tapentadol showed a mean accumulation factor of 1.6 for the parent drug and 1.8 for the major metabolite tapentadol-O-glucuronide, which are primarily determined by the dosing interval and apparent half-life of tapentadol and its metabolite.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.2"></a><p></p>
<p class="First"><span class="Italics Underline">Food Effect</span></p>
<p>The AUC and C<span class="Sub">max</span> increased by 25% and 16%, respectively, when NUCYNTA<span class="Sup">®</span> was administered after a high-fat, high-calorie breakfast. NUCYNTA<span class="Sup">®</span> may be given with or without food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3"></a><p></p>
<p class="First"><span class="Italics Underline">Distribution</span></p>
<p>Tapentadol is widely distributed throughout the body. Following intravenous administration, the volume of distribution (Vz) for tapentadol is 540 +/- 98 L. The plasma protein binding is low and amounts to approximately 20%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.4"></a><p></p>
<p class="First"><span class="Italics Underline">Metabolism and Elimination</span></p>
<p>In humans, the metabolism of tapentadol is extensive. About 97% of the parent compound is metabolized. Tapentadol is mainly metabolized via Phase 2 pathways, and only a small amount is metabolized by Phase 1 oxidative pathways. The major pathway of tapentadol metabolism is conjugation with glucuronic acid to produce glucuronides. After oral administration approximately 70% (55% O-glucuronide and 15% sulfate of tapentadol) of the dose is excreted in urine in the conjugated form. A total of 3% of drug was excreted in urine as unchanged drug. Tapentadol is additionally metabolized to N-desmethyl tapentadol (13%) by CYP2C9 and CYP2C19 and to hydroxy tapentadol (2%) by CYP2D6, which are further metabolized by conjugation. Therefore, drug metabolism mediated by cytochrome P450 system is of less importance than phase 2 conjugation.</p>
<p>None of the metabolites contributes to the analgesic activity.</p>
<p>Tapentadol and its metabolites are excreted almost exclusively (99%) via the kidneys. The terminal half-life is on average 4 hours after oral administration. The total clearance is 1530 +/- 177 ml/min.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.5"></a><p></p>
<p class="First"><span class="Italics Underline">Special Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.5.1"></a><p></p>
<p class="First">Elderly</p>
<p>The mean exposure (AUC) to tapentadol was similar in elderly subjects compared to young adults, with a 16% lower mean C<span class="Sub">max</span> observed in the elderly subject group compared to young adult subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.5.2"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></p>
<p>AUC and C<span class="Sub">max</span> of tapentadol were comparable in subjects with varying degrees of renal function (from normal to severely impaired). In contrast, increasing exposure (AUC) to tapentadol-O-glucuronide was observed with increasing degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. In subjects with mild, moderate, and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the AUC of tapentadol-O-glucuronide are 1.5-, 2.5-, and 5.5-fold higher compared with normal renal function, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.5.3"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></p>
<p>Administration of NUCYNTA<span class="Sup">®</span> resulted in higher exposures and serum levels to tapentadol in subjects with impaired hepatic function compared to subjects with normal hepatic function. The ratio of tapentadol pharmacokinetic parameters for the mild and moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> groups in comparison to the normal hepatic function group were 1.7 and 4.2, respectively, for AUC; 1.4 and 2.5, respectively, for C<span class="Sub">max</span>; and 1.2 and 1.4, respectively, for t<span class="Sub">1/2</span>. The rate of formation of tapentadol-O-glucuronide was lower in subjects with increased liver impairment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.5.4"></a><p></p>
<p class="First">Pharmacokinetic Drug Interactions</p>
<p>Tapentadol is mainly metabolized by Phase 2 glucuronidation, a high capacity/low affinity system, therefore, clinically relevant interactions caused by Phase 2 metabolism are unlikely to occur. Naproxen and probenecid increased the AUC of tapentadol by 17% and 57%, respectively. These changes are not considered clinically relevant and no change in dose is required.</p>
<p>No changes in the pharmacokinetic parameters of tapentadol were observed when acetaminophen and acetylsalicylic acid were given concomitantly.</p>
<p><span class="Italics">In vitro</span> studies did not reveal any potential of tapentadol to either inhibit or induce cytochrome P450 enzymes. Thus, clinically relevant interactions mediated by the cytochrome P450 system are unlikely to occur.</p>
<p>The pharmacokinetics of tapentadol were not affected when gastric pH or gastrointestinal motility were increased by omeprazole and metoclopramide, respectively.</p>
<p>Plasma protein binding of tapentadol is low (approximately 20%). Therefore, the likelihood of pharmacokinetic drug-drug interactions by displacement from the protein binding site is low.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-13"></a><p></p>
<h1>13 NON-CLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.1"></a><p></p>
<p class="First"><span class="Italics Underline">Carcinogenesis</span></p>
<p>Tapentadol was administered to rats (diet) and mice (oral gavage) for two years.</p>
<p>In mice, tapentadol HCl was administered by oral gavage at dosages of 50, 100 and 200 mg/kg/day for 2 years (up to 0.2 times the plasma exposure at the maximum recommended human dose [MRHD] on an area under the time-curve [AUC] basis). No increase in tumor incidence was observed at any dose level.</p>
<p>In rats, tapentadol HCl was administered in diet at dosages of 10, 50, 125 and 250 mg/kg/day for two years (up to 0.2 times in the male rats and 0.6 times in the female rats the MRHD on an AUC basis). No increase in tumor incidence was observed at any dose level.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.2"></a><p></p>
<p class="First"><span class="Italics Underline">Mutagenesis</span></p>
<p>Tapentadol did not induce gene mutations in bacteria, but was clastogenic with metabolic activation in a chromosomal aberration test in V79 cells. The test was repeated and was negative in the presence and absence of metabolic activation. The one positive result for tapentadol was not confirmed <span class="Italics">in vivo</span> in rats, using the two endpoints of chromosomal aberration and unscheduled DNA synthesis, when tested up to the maximum tolerated dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.3"></a><p></p>
<p class="First"><span class="Italics Underline">Impairment of Fertility</span></p>
<p>Tapentadol HCl was administered intravenously to male or female rats at dosages of 3, 6, or 12 mg/kg/day (representing exposures of up to approximately 0.4 times the exposure at the MRHD on an AUC basis, based on extrapolation from toxicokinetic analyses in a separate 4-week intravenous study in rats). Tapentadol did not alter fertility at any dose level. Maternal toxicity and adverse effects on embryonic development, including decreased number of implantations, decreased numbers of live conceptuses, and increased pre- and post-implantation losses occurred at dosages ≥6 mg/kg/day.</p>
</div>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="S13.2"></a><a name="section-13.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">In toxicological studies with tapentadol, the most common systemic effects of tapentadol were related to the mu-opioid receptor agonist and norepinephrine reuptake inhibition pharmacodynamic properties of the compound. Transient, dose-dependent and predominantly CNS-related findings were observed, including impaired respiratory function and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, the latter occurring in the dog at plasma levels (C<span class="Sub">max</span>) which are in the range associated with the maximum recommended human dose (MRHD).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The efficacy and safety of NUCYNTA<span class="Sup">®</span> in the treatment of moderate to severe <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> has been established in two randomized, double-blind, placebo- and active-controlled studies of moderate to severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from first metatarsal bunionectomy and end-stage <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">degenerative joint disease</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.1"></a><p></p>
<h2>14.1  Orthopedic Surgery – Bunionectomy</h2>
<p class="First">A randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study demonstrated the efficacy of 50 mg, 75 mg, and 100 mg NUCYNTA<span class="Sup">®</span> given every 4 to 6 hours for 72 hours in patients aged 18 to 80 years experiencing moderate to severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> following unilateral, first metatarsal bunionectomy surgery. Patients who qualified for the study with a baseline <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score of ≥4 on an 11-point rating scale ranging from 0 to 10 were randomized to 1 of 5 treatments. Patients were allowed to take a second dose of study medication as soon as 1 hour after the first dose on study Day 1, with subsequent dosing every 4 to 6 hours. If rescue analgesics were required, the patients were discontinued for lack of efficacy. Efficacy was evaluated by comparing the sum of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity difference over the first 48 hours (SPID48) versus placebo. NUCYNTA<span class="Sup">®</span> at each dose provided a greater reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> compared to placebo based on SPID48 values.</p>
<p>For various degrees of improvement from baseline to the 48-hour endpoint, Figure 1 shows the fraction of patients achieving that level of improvement. The figures are cumulative, such that every patient that achieves a 50% reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from baseline is included in every level of improvement below 50%. Patients who did not complete the 48-hour observation period in the study were assigned 0% improvement.</p>
<table width="100%">
<col align="center" valign="middle" width="100%">
<tbody class="Headless">
<tr class="First Toprule"><td align="center"><span class="Bold">Figure 1:      Percentage of Patients Achieving Various Levels of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Relief as Measured by <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Severity at 48 Hours Compared to Baseline- Post Operative Bunionectomy<br><br></span></td></tr>
<tr class="Botrule Last"><td align="center"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da748c7a-d2ae-1cbc-6f1a-8a6fc0402560&amp;name=nucynta-02.jpg"></td></tr>
</tbody>
</table>
<p>The proportions of patients who showed reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity at 48 hours of 30% or greater, or 50% or greater were significantly higher in patients treated with NUCYNTA<span class="Sup">®</span> at each dose versus placebo.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.2"></a><p></p>
<h2>14.2  End-Stage <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Degenerative Joint Disease</span></h2>
<p class="First">A randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study evaluated the efficacy and safety of 50 mg and 75 mg NUCYNTA<span class="Sup">®</span> given every 4 to 6 hours during waking hours for 10 days in patients aged 18 to 80 years, experiencing moderate to severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from end stage <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">degenerative joint disease</span> of the hip or knee, defined as a 3-day mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score of ≥5 on an 11-point <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity scale, ranging from 0 to 10. <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> scores were assessed twice daily and assessed the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> the patient had experienced over the previous 12 hours. Patients were allowed to continue non-opioid analgesic therapy for which they had been on a stable regimen before screening throughout the study. Eighty-three percent (83%) of patients in the tapentadol treatment groups and the placebo group took such <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> during the study. The 75 mg treatment group was dosed at 50 mg for the first day of the study, followed by 75 mg for the remaining nine days. Patients requiring rescue analgesics other than study medication were discontinued for lack of efficacy. Efficacy was evaluated by comparing the sum of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity difference (SPID) versus placebo over the first five days of treatment. NUCYNTA<span class="Sup">®</span> 50 mg and 75 mg provided improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> compared with placebo based on the 5-Day SPID.</p>
<p>For various degrees of improvement from baseline to the Day 5 endpoint, Figure 2 shows the fraction of patients achieving that level of improvement. The figures are cumulative, such that every patient that achieves a 50% reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from baseline is included in every level of improvement below 50%. Patients who did not complete the 5-day observation period in the study were assigned 0% improvement.</p>
<table width="100%">
<col align="center" valign="middle" width="100%">
<tbody class="Headless">
<tr class="First Toprule"><td align="center"><span class="Bold">Figure 2:      Percentage of Patients Achieving Various Levels of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Relief as Measured by Average <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Severity for the Previous 12 hours, Measured on Study Day 5 Compared to Baseline -- End Stage <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Degenerative Joint Disease</span><br><br></span></td></tr>
<tr class="Botrule Last"><td align="center"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da748c7a-d2ae-1cbc-6f1a-8a6fc0402560&amp;name=nucynta-03.jpg"></td></tr>
</tbody>
</table>
<p>The proportions of patients who showed reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity at 5 days of 30% or greater, or 50% or greater were significantly higher in patients treated with NUCYNTA<span class="Sup">®</span> at each dose versus placebo.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Physicians are advised to discuss the following issues with patients for whom they prescribe NUCYNTA<span class="Sup">®</span>:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Instructions for Use</h2>
<p class="First">Patients should be advised NUCYNTA<span class="Sup">®</span> should be taken only as directed and to report episodes of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and adverse experiences occurring during therapy to their physician. Individualization of dosage is essential to make optimal use of this medication. Patients should be advised not to adjust the dose of NUCYNTA<span class="Sup">®</span> without consulting their physician <span class="Italics">[see<a href="#S2"> Dosage and Administration (2)</a>]. </span>Patients should be advised that it may be appropriate to taper dosing when discontinuing treatment with NUCYNTA<span class="Sup">®</span> as withdrawal symptoms may occur <span class="Italics">[see<a href="#S9.3"> Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (9.3)</a>]</span>. The physician can provide a dose schedule to accomplish a gradual discontinuation of the medication.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.2"></a><a name="section-15.2"></a><p></p>
<h2>17.2 Misuse and Abuse</h2>
<p class="First">Patients should be advised that NUCYNTA<span class="Sup">®</span> is a potential drug of abuse. Patients should protect NUCYNTA<span class="Sup">®</span> from <span class="product-label-link" type="condition" conceptid="4087298" conceptname="Theft">theft</span>, and NUCYNTA<span class="Sup">®</span> should never be given to anyone other than the individual for whom NUCYNTA<span class="Sup">®</span> was prescribed <span class="Italics">[see<a href="#S5.4"> Warnings and Precautions (5.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.3"></a><a name="section-15.3"></a><p></p>
<h2>17.3 Interference with Cognitive and Motor Performance</h2>
<p class="First">As NUCYNTA<span class="Sup">®</span> has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles <span class="Italics">[see<a href="#S5.5"> Warnings and Precautions (5.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.4"></a><a name="section-15.4"></a><p></p>
<h2>17.4 Pregnancy</h2>
<p class="First">Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with NUCYNTA<span class="Sup">®</span><span class="Italics"> [see<a href="#S8.1"> Use in Specific Populations (8.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.5"></a><a name="section-15.5"></a><p></p>
<h2>17.5 Nursing</h2>
<p class="First">Patients should be advised not to breast-feed an infant during treatment with NUCYNTA<span class="Sup">®</span><span class="Italics"> [see<a href="#S8.3"> Use in Specific Populations (8.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.6"></a><a name="section-15.6"></a><p></p>
<h2>17.6  Monoamine Oxidase Inhibitors</h2>
<p class="First">Patients should be informed not to take NUCYNTA<span class="Sup">®</span> while using any drugs that inhibit monoamine oxidase. Patients should not start any new medications while taking NUCYNTA<span class="Sup">®</span> until they are assured by their healthcare provider that the new medication is not a monoamine oxidase inhibitor.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.7"></a><a name="section-15.7"></a><p></p>
<h2>17.7  <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></h2>
<p class="First">Patients should be informed that NUCYNTA<span class="Sup">®</span> could cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> if they are at risk for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or have <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>. Such patients should be advised to use NUCYNTA<span class="Sup">®</span> with care <span class="Italics">[see<a href="#S5.7"> Warnings and Precautions (5.7)</a>]</span>. Patients should be advised to stop taking NUCYNTA<span class="Sup">®</span> if they have a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> while taking NUCYNTA<span class="Sup">®</span> and call their healthcare provider right away.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.8"></a><a name="section-15.8"></a><p></p>
<h2>17.8  <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></h2>
<p class="First">Patients should be informed that NUCYNTA<span class="Sup">®</span> could cause rare but potentially life-threatening conditions resulting from concomitant administration of serotonergic drugs (including Serotonin Reuptake Inhibitors, Serotonin and Norepinephrine Reuptake Inhibitors and tricyclic antidepressants) <span class="Italics">[see<a href="#S5.8"> Warnings and Precautions (5.8)</a>]</span>.</p>
<p>Patients should be advised to inform their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs as there is a potential for interactions <span class="Italics">[see<a href="#S7"> Drug Interactions (7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.9"></a><a name="section-15.9"></a><p></p>
<h2>17.9  Alcohol</h2>
<p class="First">Patients should be advised to avoid alcohol while taking NUCYNTA<span class="Sup">®</span><span class="Italics"> [see<a href="#S7.3"> Drug Interactions (7.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.10"></a><a name="section-15.10"></a><p></p>
<h2>17.10 Medication Guide</h2>
<p class="First">See<a href="#medguide"> Medication Guide</a>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="medguide"></a><a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">MEDICATION GUIDE</span></p>
<p><span class="Bold">NUCYNTA<span class="Sup">®</span><span class="Underline"> (new-SINN-tah)</span></span></p>
<p><span class="Bold">(tapentadol)</span></p>
<p><span class="Bold">immediate-release oral tablets   C-II</span></p>
<table width="100%">
<col align="left" valign="top" width="100%">
<tbody class="Headless"><tr class="First Last"><td class="Lrule Rrule" align="left"><ul>
<li><span class="Bold">NUCYNTA<span class="Sup">®</span> is a federally controlled substance (C-II) because it can be abused. Keep NUCYNTA<span class="Sup">®</span> in a safe place to prevent <span class="product-label-link" type="condition" conceptid="4087298" conceptname="Theft">theft</span>. Selling or giving away NUCYNTA<span class="Sup">®</span> may harm others, and is against the law. </span></li>
<li><span class="Bold">Tell your doctor if you (or a family member) have ever abused or been dependent on alcohol, prescription medicines, or street drugs. </span></li>
</ul></td></tr></tbody>
</table>
<p><span class="Bold">Read the Medication Guide that comes with NUCYNTA<span class="Sup">®</span> before you start taking it and each time you get a new prescription. There may be new information. This Medication Guide does not take the place of talking to your doctor about your medical condition or your treatment. Talk to your doctor if you have any questions. </span></p>
<p><span class="Bold">What is the most important information I should know about NUCYNTA<span class="Sup">®</span>?</span></p>
<p>NUCYNTA<span class="Sup">®</span> is a tablet that contains tapentadol, a strong medicine that is a <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicine.</p>
<p>Use NUCYNTA<span class="Sup">®</span> exactly how your doctor tells you to. Do not use NUCYNTA<span class="Sup">®</span> if it has not been prescribed for you.</p>
<p>You should not take NUCYNTA<span class="Sup">®</span> if your <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> is mild and can be controlled with other <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicines such as non-steroidal anti-inflammatory medicines (NSAIDS) or acetaminophen.</p>
<p><span class="Bold">What is NUCYNTA<span class="Sup">®</span>?</span></p>
<ul><li>NUCYNTA<span class="Sup">®</span> is a prescription medicine that is used in adults 18 years of age or older to treat moderate to severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> that is expected to last a short time. <p class="First">NUCYNTA<span class="Sup">®</span> is for short-term use only because the risks for withdrawal symptoms, abuse and addiction are higher when NUCYNTA<span class="Sup">®</span> is used longer.</p>
</li></ul>
<p><a name="whoshouldnot"></a><span class="Bold">Who should not take NUCYNTA<span class="Sup">®</span>?</span></p>
<p><span class="Bold">Do not take NUCYNTA<span class="Sup">®</span> if you:</span></p>
<ul>
<li> have severe lung problems</li>
<li> have a gastrointestinal problem called <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> in which the intestines are not working normally.</li>
<li> take a monoamine oxidase inhibitor (MAOI) medicine or have taken an MAOI within the last 14 days. Ask your doctor or pharmacist if any of your medicines is an MAOI.</li>
</ul>
<p><span class="Bold">What should I tell my doctor before taking NUCYNTA<span class="Sup">®</span>?</span></p>
<p><span class="Bold">NUCYNTA<span class="Sup">®</span> may not be right for you. </span>Tell your doctor about all your medical conditions, including if you have:</p>
<ul>
<li>trouble breathing or lung problems</li>
<li>or had a <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span></li>
<li>liver or kidney problems</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></li>
<li>dependency problems with alcohol</li>
<li>pancreas or gall bladder problems</li>
<li>past or present <span class="product-label-link" type="condition" conceptid="4279309" conceptname="Substance abuse">substance abuse</span> or <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug addiction</span>. There is a risk of abuse or addiction with narcotic <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicines. If you have abused drugs in the past, you may have a higher chance of developing abuse or addiction again while using NUCYNTA<span class="Sup">®</span>.</li>
<li>are pregnant or plan to become pregnant</li>
<li>are breast-feeding. You should not breast-feed while taking NUCYNTA<span class="Sup">®</span>.</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take,</span> including prescription and nonprescription medicines, vitamins, and herbal supplements. Using NUCYNTA<span class="Sup">®</span> with other medicines can cause serious side effects. The doses of some other medicines may need to be changed. Your doctor can tell you what medicines can be safely taken with NUCYNTA<span class="Sup">®</span>. Especially tell your doctor if you take:</p>
<ul>
<li>
<span class="Bold">Monoamine Oxidase Inhibitors (MAOIs)</span>. See<a href="#whoshouldnot"> "Who should not take NUCYNTA</a><span class="Sup">®</span>."</li>
<li>
<span class="Bold">any medicine that makes you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span>. </span>NUCYNTA<span class="Sup">®</span> can make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span> and affect your breathing. Taking these medicines together can be dangerous.</li>
</ul>
<p><span class="Bold">How should I take NUCYNTA<span class="Sup">®</span>?</span></p>
<ul>
<li> Do not take NUCYNTA<span class="Sup">®</span> unless it has been prescribed for you by your doctor.</li>
<li> Take NUCYNTA<span class="Sup">®</span> exactly as prescribed by your doctor.</li>
<li>
<span class="Bold">Do not change the dose of NUCYNTA<span class="Sup">®</span> unless your doctor tells you to. </span>Your doctor may change your dose after seeing how the medicine affects you. Do not use NUCYNTA<span class="Sup">®</span> more often than prescribed. Call your doctor if your <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> is not well controlled while taking NUCYNTA<span class="Sup">®</span>.</li>
<li> Follow your doctor's instructions about how to slowly stop taking NUCYNTA<span class="Sup">®</span> to help lessen withdrawal symptoms.</li>
<li> NUCYNTA<span class="Sup">®</span> can be taken with or without food.</li>
</ul>
<p><span class="Bold">What should I avoid while taking NUCYNTA<span class="Sup">®</span>?</span></p>
<ul>
<li> Do not drive, operate machinery, or participate in any other possibly dangerous activities until you know how you react to this medicine. NUCYNTA<span class="Sup">®</span> can make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span>.</li>
<li> You should not drink alcohol while using NUCYNTA<span class="Sup">®</span>. Alcohol increases your chance of having dangerous side effects.</li>
</ul>
<p><span class="Bold">What are the possible side effects of NUCYNTA<span class="Sup">®</span>?</span></p>
<p><span class="Bold">NUCYNTA<span class="Sup">®</span> can cause serious side effects including:</span></p>
<ul>
<li>
<span class="Bold">Life-threatening breathing problems. Call your doctor right away or get emergency medical help if you:</span><ul class="Disc">
<li>have trouble breathing, or have slow or <span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">shallow breathing</span></li>
<li>have a slow heartbeat</li>
<li>have severe <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span></li>
<li>have <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin</li>
<li>feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, dizzy, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span>, or can not think, walk or talk normally</li>
<li>have a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span></li>
<li>have <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span></li>
</ul>
</li>
<li>
<span class="Bold">Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></span>. NUCYNTA<span class="Sup">®</span> can cause physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. Talk to your doctor about slowly stopping NUCYNTA<span class="Sup">®</span> to avoid getting sick with withdrawal symptoms. You could become sick with uncomfortable symptoms because your body has become used to the medicine. Tell your doctor if you have any of these symptoms of withdrawal:  feeling anxious, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep problems</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">shivering</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, upper respiratory symptoms, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, hair "standing on end."  Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is not the same as <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug addiction</span>. Your doctor can tell you more about the differences between physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug addiction</span>.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span>. </span><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> is a rare, life-threatening problem that could happen if you take NUCYNTA<span class="Sup">®</span> with Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Monoamine Oxidase Inhibitors (MAOIs), triptans or certain other medicines. Call your doctor or get medical help right away if you have any one or more of the these symptoms:  you feel <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span>, have <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, rapid heart beat, feel overheated, loss of coordination, over active reflexes, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span>. NUCYNTA<span class="Sup">®</span> can cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in people who are at risk for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or who have <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>. Tell your doctor right away if you have a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> and stop taking NUCYNTA<span class="Sup">®</span>.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Low blood pressure</span>. </span>This can make you feel dizzy if you get up too fast from sitting or lying down.</li>
</ul>
<p><span class="Bold">The common side effects with NUCYNTA<span class="Sup">®</span></span> are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> is a common side effect of all opioid medicines. Talk to your doctor about the use of laxatives and stool softeners to prevent or treat <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> while taking NUCYNTA<span class="Sup">®</span>.</p>
<p>Tell your doctor about any side effect that bothers you or that does not go away. These are not all the possible side effects of NUCYNTA<span class="Sup">®</span>.  For a complete list, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store NUCYNTA<span class="Sup">®</span>?</span></p>
<ul>
<li> Store NUCYNTA<span class="Sup">®</span> at 59ºF to 86ºF (15ºC to 30ºC). Keep NUCYNTA<span class="Sup">®</span> tablets dry.</li>
<li> Dispose of NUCYNTA<span class="Sup">®</span> tablets you no longer need. </li>
</ul>
<p><span class="Bold">Keep NUCYNTA<span class="Sup">®</span> in a safe place out of the reach of children.</span></p>
<p><span class="Bold">General information about NUCYNTA<span class="Sup">®</span></span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use NUCYNTA<span class="Sup">®</span> for a condition for which it was not prescribed. <span class="Bold">Do not give NUCYNTA<span class="Sup">®</span> to other people, even if they have the same symptoms you have. Sharing NUCYNTA<span class="Sup">®</span> could be harmful and is against the law.</span></p>
<p>This Medication Guide summarizes the most important information about NUCYNTA<span class="Sup">®</span>. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about NUCYNTA<span class="Sup">®</span> that is written for doctors. For more information about NUCYNTA<span class="Sup">®</span> call 1-800-526-7736.</p>
<p><span class="Bold">What are the ingredients in NUCYNTA<span class="Sup">®</span>?</span></p>
<p><span class="Bold">Active Ingredient: tapentadol </span></p>
<p><span class="Bold">Inactive ingredients: </span>  microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, povidone, magnesium stearate, and Opadry<span class="Sup">®</span> II, a proprietary film-coating mixture containing polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and aluminum lake coloring.</p>
<p><span class="Bold">This Medication Guide has been approved by the U.S. Food and Drug Administration. </span></p>
<p>Revised: June 2010</p>
<p>Manufactured by: <br>Janssen Ortho, LLC <br>Gurabo, PR 00778</p>
<p>Manufactured for: <br>PriCara<span class="Sup">®</span>, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. <br>Raritan, NJ 08869</p>
<p>© Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2009</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>Nucynta 50mg (CII) Tablet</h1>
<div class="Figure"><img alt="Image File" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da748c7a-d2ae-1cbc-6f1a-8a6fc0402560&amp;name=label1datamaxfda263.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NUCYNTA 		
					</strong><br><span class="contentTableReg">tapentadol hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63629-4179(NDC:50458-820)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>tapentadol hydrochloride</strong> (tapentadol) </td>
<td class="formItem">tapentadol</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>povidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyvinyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>aluminum oxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (round and biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">O;M;50</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63629-4179-5</td>
<td class="formItem">10  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:63629-4179-4</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:63629-4179-3</td>
<td class="formItem">120  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:63629-4179-2</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:63629-4179-1</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022304</td>
<td class="formItem">06/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Bryant Ranch Prepack
							(171714327)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Bryant Ranch Prepack (171714327)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Janssen Ortho, LLC</td>
<td class="formItem"></td>
<td class="formItem">062191882</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Bryant Ranch Prepack</td>
<td class="formItem"></td>
<td class="formItem">171714327</td>
<td class="formItem">REPACK, RELABEL</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5fe2bf15-2e04-301a-f300-c5d01a3a551c</div>
<div>Set id: da748c7a-d2ae-1cbc-6f1a-8a6fc0402560</div>
<div>Version: 1</div>
<div>Effective Time: 20090601</div>
</div>
</div> <div class="DistributorName">Bryant Ranch Prepack</div></p>
</body></html>
